HomeCompareXXMMF vs JNJ

XXMMF vs JNJ: Dividend Comparison 2026

XXMMF yields 3571.43% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 XXMMF wins by $2410861919878.50M in total portfolio value
10 years
XXMMF
XXMMF
● Live price
3571.43%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2410861919878.53M
Annual income
$2,285,003,389,352,781,300.00
Full XXMMF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — XXMMF vs JNJ

📍 XXMMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXXMMFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XXMMF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XXMMF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XXMMF
Annual income on $10K today (after 15% tax)
$303,571.43/yr
After 10yr DRIP, annual income (after tax)
$1,942,252,880,949,864,200.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, XXMMF beats the other by $1,942,252,880,949,860,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XXMMF + JNJ for your $10,000?

XXMMF: 50%JNJ: 50%
100% JNJ50/50100% XXMMF
Portfolio after 10yr
$1205430959939.28M
Annual income
$1,142,501,694,676,393,000.00/yr
Blended yield
94.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

XXMMF
No analyst data
Altman Z
-55.4
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XXMMF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXXMMFJNJ
Forward yield3571.43%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$2410861919878.53M$30.3K
Annual income after 10y$2,285,003,389,352,781,300.00$4,689.40
Total dividends collected$2402234622286.96M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: XXMMF vs JNJ ($10,000, DRIP)

YearXXMMF PortfolioXXMMF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$367,843$357,142.86$10,592$272.30+$357.3KXXMMF
2$12,671,391$12,277,798.97$11,289$357.73+$12.66MXXMMF
3$408,832,799$395,274,410.34$12,123$472.89+$408.82MXXMMF
4$12,356,356,289$11,918,905,194.31$13,141$629.86+$12356.34MXXMMF
5$349,885,767,337$336,664,466,108.04$14,408$846.81+$349885.75MXXMMF
6$9,283,796,217,812$8,909,418,446,760.99$16,021$1,151.60+$9283796.20MXXMMF
7$230,868,855,425,769$220,935,193,472,710.20$18,122$1,588.22+$230868855.41MXXMMF
8$5,381,798,251,219,442$5,134,768,575,913,869.00$20,930$2,228.20+$5381798251.20MXXMMF
9$117,624,794,883,873,220$111,866,270,755,068,420.00$24,792$3,191.91+$117624794883.85MXXMMF
10$2,410,861,919,878,526,000$2,285,003,389,352,781,300.00$30,274$4,689.40+$2410861919878.50MXXMMF

XXMMF vs JNJ: Complete Analysis 2026

XXMMFStock

Ximen Mining Corp. engages in the acquisition, exploration, and evaluation of mineral properties in Canada. The company primarily explores for gold, silver, lead, and zinc deposits. Its principal project is the Brett Epithermal Gold Project located in British Columbia. The company also acquires 100% interest in the Wild Horse Creek property that consists of 139 mineral claims covering an area of approximately 12,767 hectares located in southern British Columbia. It has option to acquire the Kenville Gold Mine project located west of Nelson, British Columbia. The company was formerly known as Elm Tree Minerals Inc. and changed its name to Ximen Mining Corp. in September 2013. Ximen Mining Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Full XXMMF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this XXMMF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XXMMF vs SCHDXXMMF vs JEPIXXMMF vs OXXMMF vs KOXXMMF vs MAINXXMMF vs ABBVXXMMF vs MRKXXMMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.